Cargando…

SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron

Mostrar otras versiones (1)

The wide spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of immune responses to different spike protein versions. Here, we compare neutralization of variants of concern, inclu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laurie, Matthew T, Liu, Jamin, Sunshine, Sara, Peng, James, Black, Douglas, Mitchell, Anthea M, Mann, Sabrina A, Pilarowski, Genay, Zorn, Kelsey C, Rubio, Luis, Bravo, Sara, Marquez, Carina, Sabatino, Joseph J, Mittl, Kristen, Petersen, Maya, Havlir, Diane, DeRisi, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755395/ https://www.ncbi.nlm.nih.gov/pubmed/34979030 http://dx.doi.org/10.1093/infdis/jiab635

Ejemplares similares

SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron
por: Laurie, Matthew T, et al.
Publicado: (2021)

COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods
por: Marquez, Carina, et al.
Publicado: (2022)

Estimation of Secondary Household Attack Rates for Emergent Spike L452R Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Detected by Genomic Surveillance at a Community-Based Testing Site in San Francisco
por: Peng, James, et al.
Publicado: (2021)

Viral Load Among Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Persons Infected With the SARS-CoV-2 Delta Variant
por: Acharya, Charlotte B, et al.
Publicado: (2022)

Performance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco
por: Pilarowski, Genay, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Dynamics and Immune Responses in a Household of Vaccinated Persons
por: Liu, Jamin, et al.
Publicado: (2022)

Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco
por: Pilarowski, Genay, et al.
Publicado: (2020)

Field assessment of BinaxNOW antigen tests as COVID-19 treatment entry point at a community testing site in San Francisco during evolving omicron surges
por: Schrom, John, et al.
Publicado: (2023)

Estimation of secondary household attack rates for emergent SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco
por: Peng, James, et al.
Publicado: (2021)

Field Performance and Public Health Response Using the BinaxNOW(TM) Rapid Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection Assay During Community-Based Testing
por: Pilarowski, Genay, et al.
Publicado: (2020)

High Parental Vaccine Motivation at a Neighborhood-Based Vaccine and Testing Site Serving a Predominantly Latinx Community
por: Naso, Jamie, et al.
Publicado: (2021)

Persistence of Ambigrammatic Narnaviruses Requires Translation of the Reverse Open Reading Frame
por: Retallack, Hanna, et al.
Publicado: (2021)

Genome-Wide Knockout Screen Identifies Human Sialomucin CD164 as an Essential Entry Factor for Lymphocytic Choriomeningitis Virus
por: Liu, Jamin, et al.
Publicado: (2022)

High Likelihood of Accepting COVID-19 Vaccine in a Latinx Community at High SARS-CoV-2 Risk in San Francisco
por: Peng, James, et al.
Publicado: (2021)

The COVID-19 Symptom to Isolation Cascade in a Latinx Community: A Call to Action
por: Rubio, Luis A, et al.
Publicado: (2021)

Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study
por: Gottlieb, Michael, et al.
Publicado: (2023)

A multi-component, community-based strategy to facilitate COVID-19 vaccine uptake among Latinx populations: From theory to practice
por: Marquez, Carina, et al.
Publicado: (2021)

Antibody Level Predicts the Clinical Course of Breakthrough Infection of COVID-19 Caused by Delta and Omicron Variants: A Prospective Cross-Sectional Study
por: Kim, Min Hyung, et al.
Publicado: (2022)

Kinetics of SARS-CoV-2 Serum Antibodies Through the Alpha, Delta, and Omicron Surges Among Vaccinated Health Care Workers at a Boston Hospital
por: Dodge, Maura C, et al.
Publicado: (2023)

Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022
por: Hoeve, Christina E, et al.
Publicado: (2023)

BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration
por: Ionescu, Iulia G, et al.
Publicado: (2023)

Association between self-reported masking behavior and SARS-CoV-2 infection wanes from Pre-Delta to Omicron-predominant periods — North Carolina COVID-19 Community Research Partnership (NC-CCRP)
por: Tjaden, Ashley H., et al.
Publicado: (2023)

Extensive Epigenetic Changes Accompany Terminal Differentiation of Mouse Hepatocytes After Birth
por: Cannon, Matthew V., et al.
Publicado: (2016)

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C Paul, et al.
Publicado: (2022)

Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients
por: Zhang, Lei, et al.
Publicado: (2023)

Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021
por: Klaassen, Fayette, et al.
Publicado: (2022)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
por: Ison, Michael G, et al.
Publicado: (2023)

Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice
por: Jansen van Vuren, Petrus, et al.
Publicado: (2022)

Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era
por: McCreary, Erin K, et al.
Publicado: (2022)

Assessment of the Effectiveness of Omicron Transmission Mitigation Strategies for European Universities Using an Agent-Based Network Model
por: Lasser, Jana, et al.
Publicado: (2022)

Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa
por: Jassat, Waasila, et al.
Publicado: (2022)

Delta-Omicron recombinant escapes therapeutic antibody neutralization
por: Duerr, Ralf, et al.
Publicado: (2023)

Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant
por: Risk, Malcolm, et al.
Publicado: (2022)

Chemical Rescue of Malaria Parasites Lacking an Apicoplast Defines Organelle Function in Blood-Stage Plasmodium falciparum
por: Yeh, Ellen, et al.
Publicado: (2011)

Description of Hospitalizations due to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Based on Vaccination Status
por: Moffa, Matthew A, et al.
Publicado: (2022)

Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study)
por: Arashiro, Takeshi, et al.
Publicado: (2022)

Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study
por: Malahe, S Reshwan K, et al.
Publicado: (2022)

Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study
por: Chung, Hannah, et al.
Publicado: (2022)

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
por: Gliga, Smaranda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r9r9d2inpd78ne0rqun3bla97r